🇺🇸

US SEC Filing Intelligence

· daily

NASA & Space Contracts Intelligence — May 20, 2026

This digest covers $1.28B in NASA-only contracts awarded to three entities—Northrop Grumman, Caltech (JPL), and RTX Corp (Raytheon)—with zero defense-related obligations, underscoring a pure civilian space and science procurement theme. The highest-conviction signal is Northrop Grumman's $569.5M firm-fixed-price delivery order for the JPSS-2 spacecraft, a 13-year program that adds a large, durable revenue stream to its space systems segment but carries execution risk on a complex polar satellite mission. A key risk is the fixed-price structure on Northrop Grumman's contract, which could compress margins if cost overruns occur, while the two Caltech awards ($515M combined) offer no direct equity upside due to their cost-only or cost-plus-fee structures. The aggregate data reveals a stable, long-duration NASA investment cycle in polar weather satellites and early-stage space R&D, with no near-term re-compete pressure on the largest awards.

4 total filings
· daily

All HHS Contracts — May 20, 2026

Over a single-day period (May 20, 2026), HHS awarded $272.9M in obligations across four contracts, with 2 of 4 defense-related (BARDA) totaling $134.8M, signaling sustained biodefense and health security prioritization. The dominant theme is HHS/BARDA investment in antimicrobial resistance (AMR) and medical countermeasures, led by a $72.1M Venatorx Pharmaceuticals award with a $318.6M ceiling through 2032. The highest-conviction signal is Venatorx's cost-plus-fixed-fee structure and long performance period, providing low-risk, durable revenue in a high-priority national security area. Key risk: SELUX Diagnostics' contract ends May 2025, limiting future upside and creating a potential revenue cliff for that small business.

4 total filings
· daily

Mega Contracts Monitor ($100M+) — May 20, 2026

This digest covers $1.366 billion in civilian-only mega contracts (0/4 defense-related) awarded on a single day, May 20, 2026, with an average signal strength of 6.0/10. NASA dominates the period, accounting for $1.215 billion (89%) of total obligations across three awards to Northrop Grumman, Caltech/JPL, and RTX Corp (Raytheon). The highest-conviction signal is Northrop Grumman's $569.5M firm-fixed-price delivery order for the JPSS-2 spacecraft, a 13-year program with 8/10 bullish strength. Key risk: the fixed-price structure on a complex space vehicle introduces execution risk, while the civilian-only mix means no direct defense budget tailwind from NDAA priorities. The Department of Interior's $151.7M award to Centene's Magellan Federal for personal financial counselors is a neutral, non-core support contract with limited margin upside due to T&M pricing.

4 total filings
· daily

High-Value Federal Grants ($5M+) — May 20, 2026

This digest of 11 high-value federal grants, totaling $1.87 billion, reveals a pronounced civilian agency tilt, with only 2 of 11 contracts defense-related. NASA dominates the award landscape, accounting for over $1.28 billion across four contracts, including a $569.5 million firm-fixed-price delivery order to Northrop Grumman for the JPSS-2 spacecraft—the highest-conviction bullish signal. The strongest cross-contract pattern is NASA's sustained investment in space R&D and satellite programs, which benefits primes like Northrop Grumman and RTX Corp. However, the neutral average signal strength (5.2/10) and the absence of any bearish signals mask execution risk on fixed-price contracts and budget uncertainty under a potential Continuing Resolution. Key watch items include Northrop Grumman's JPSS-2 delivery milestones and the exercise of options on RTX's $200 million Landis flight instrument contract.

11 total filings
· daily

All NASA Contracts — May 20, 2026

This digest covers $1.28 billion in NASA obligations from May 20, 2026, with zero defense-related awards, underscoring a pure civilian space and science R&D theme. The highest-conviction signal is Northrop Grumman's $569.5M firm-fixed-price delivery order for the JPSS-2 spacecraft, a long-duration (13-year) program that adds substantial backlog to its space systems segment but carries execution risk on a complex polar satellite mission. A key risk is the $445M Caltech sole-source award for JPL management, which concentrates NASA's early-stage R&D spending with a non-profit entity offering no direct public equity exposure. Investors should watch for JPSS-2 delivery milestones and NASA's Earth science budget allocations for the $200M Raytheon Landis instrument contract.

4 total filings
· daily

S&P 500 Technology Sector SEC Filings — May 20, 2026

The S&P 500 Technology sector is rapidly bifurcating between AI-driven hyper-growth and terrestrial restructuring. Leading the charge, **NVIDIA** delivered an extraordinary +85% YoY revenue surge to $81.6B, while **Analog Devices** rode the industrial rebound to +37% YoY growth, their highest in recent history. However, this momentum is juxtaposed against significant operational tightening: **Intuit** announced a 17% workforce reduction and up to $340M in charges, and **Aditxt** faces a liquidity crisis with cash dwindling to $269K and a ballooning $35M stockholder deficit. Capital allocation is mixed; NVIDIA raised its dividend 25x (to $0.25) and added $80B in buyback authority, while Salesforce aggressively repurchased 103M shares, distorting governance metrics. The AI infrastructure buildout is the dominant theme—NVIDIA's Data Center revenue hit $75.2B (+92% YoY)—but supply chain buildup (NVIDIA inventories +20% QoQ to $25.8B) and China revenue exclusion in guidance present notable risks. Insider activity was sparse in this batch, reducing conviction signals, but compensation-related shareholder dissent at **Iridium** (13.2% against say-on-pay) flags governance tension.

9 high priority 12 medium 21 total filings
· daily

Nasdaq 100 Stocks SEC Filings — May 20, 2026

The May 20, 2026 batch of 23 NASDAQ-100 filings reveals a sharply bifurcated market: mega-cap semiconductor leaders NVIDIA and Analog Devices post explosive growth (85% and 37% YoY revenue gains), while micro-cap clinical-stage and pre-revenue companies (Immunovant, Aditxt, Loan AI, Mosaic) show accelerating cash burns, widening losses, and deteriorating balance sheets. Period-over-period comparisons confirm an AI-driven investment cycle is compressing margins at scale—NVIDIA's R&D spend surged 58.5% YoY, Intuit's R&D rose 18.8%—despite strong top-line growth. Capital allocation trends diverge sharply: NVIDIA announced an $80B buyback and 25x dividend hike, and Starbucks retired $1.32B in debt, contrasting with cash-strapped biotechs drawing on dilutive equity offerings (Immunovant raised $544M). Insider activity shows no direct selling signals in this batch, but shareholder dissent at Iridium (13.2% against say-on-pay) and ADI's $29M severance program hint at governance and restructuring risks. The portfolio-level takeaway is a 'growth-at-a-cost' regime favoring dominant AI beneficiaries, while speculative names face a liquidity crunch.

10 high priority 13 medium 23 total filings
· daily

S&P 500 Financials Sector SEC Filings — May 20, 2026

The 50 filings from the S&P 500 Financials sector and related companies reveal a bifurcated landscape: traditional financial institutions face margin compression and rising credit losses, while asset managers and fintech innovators push into digital assets and alternative structures. Key period-over-period trends show revenue growth in select industrial and tech-adjacent financials (Analog Devices +37% YoY, CAVA +32.1%), but net income declines dominate the banking and REIT subsectors (Sachem Capital swung to -$6.1M net loss, PrimeEnergy -52.5% net income). The most critical developments include Morgan Stanley's dual crypto trust filings (Solana and Ethereum), signaling institutional crypto adoption acceleration, and the $2.25B Moderna settlement by Roivant Sciences, which creates a massive cash position for biotech deployment. Portfolio-level patterns reveal aggressive capital allocation toward share repurchases (News Corp $1B program, Salesforce $25B ASR) versus organic reinvestment, while insider activity remains muted across the sample, with no major CEO purchases or sales detected. The data suggests investors should favor asset-light, growth-oriented financial platforms over traditional lenders facing credit cycle headwinds.

25 high priority 25 medium 50 total filings
· daily

S&P 500 Consumer Staples Sector SEC Filings — May 20, 2026

The 50 filings for S&P 500 Consumer Staples on May 20, 2026, reveal a sector in transition, with a strong undercurrent of financial engineering and capital market activity, but limited direct operational data from core staples companies. Key themes include significant debt offerings and refinancings (Eli Lilly, Travel + Leisure, Wells Fargo), leadership transitions (Choice Hotels, Philip Morris), and a major M&A deal (Envirotech Vehicles/Azio AI). Period-over-period data from the limited set of consumer-related companies shows a mixed picture: Haemonetics reported a 2% revenue decline and a 42% net income drop, while CorVel showed 7% revenue growth and 17% EPS growth. The most actionable insights come from capital allocation moves, such as Eli Lilly's $8.94B debt raise to fund a pending acquisition and Travel + Leisure's $900M refinancing, signaling strategic shifts. Insider activity is sparse, but the significant shareholder dissent at Verra Mobility (33% withheld votes) and the 40% opposition to Castellum's stock plan are notable governance risk flags. The overall sentiment is neutral to mixed, with opportunities in companies executing well (CorVel) and risks in those with deteriorating fundamentals (Haemonetics, KonaTel).

25 high priority 25 medium 50 total filings
· daily

S&P 500 Industrials Sector SEC Filings — May 20, 2026

The 50 filings for S&P 500 Industrials on May 20, 2026, reveal a bifurcated landscape: strong cyclical recovery in semiconductors (Analog Devices revenue +37% YoY) contrasts with acute distress in small-cap industrials (Treasure Global net loss swing of -$3.58M YoY, Ionetix pre-revenue cash burn). The dominant themes are leadership transitions (Choice Hotels, Diamondback Energy, Schrodinger) and capital market activity (S&P Global $2B spin-off debt, Deep Fission $150M IPO, GEN Restaurant $50M shelf). Cybersecurity risk is elevated (West Pharmaceutical attack with data exfiltration). Insider activity is notably absent across filings, but capital allocation signals are mixed: dividend increases (TrustCo $0.38/sh) vs. dilutive offerings (NanoViricides $2M, WidePoint $5M). The sector shows a clear divergence between large-cap industrial strength and micro-cap fragility, with M&A integration (Santander/Webster) and IPOs providing catalyst opportunities.

24 high priority 26 medium 50 total filings
· daily

S&P 500 Energy Sector SEC Filings — May 20, 2026

The four filings in the S&P 500 Energy sector for May 20, 2026, reveal a mix of routine governance and financial distress. COPT Defense Properties and Mid-America Apartments (MAA) held annual meetings with strong shareholder support, though MAA's director Tamara Fischer faced notable opposition (91.1% for). Halliburton's meeting also passed all proposals, but director T.M. Edwards Young received significant opposition (92.1M votes against). Copley Acquisition Corp reported a net income turnaround to $1.29M from a loss of $74,699 YoY, driven by trust dividends, but cash plummeted 94% to $4,235 and expenses surged 255%. No period-over-period comparisons for revenue or margins exist as these are non-operational entities. No insider trading activity was reported. Forward-looking data is absent except for Copley's ongoing working capital loan. Capital allocation is limited to dividend income for Copley. The key theme is the divergence between stable, well-governed REITs and a cash-burning SPAC with no operating revenue.

1 high priority 3 medium 4 total filings
· daily

US Material Events SEC 8-K Filings — May 20, 2026

The May 20, 2026, filings reveal a market dominated by strategic capital management and leadership transitions, with a notable undercurrent of financial distress in smaller-cap companies. The most significant capital market activity includes a massive $3.75 billion revolving credit facility for Williams Companies and a $1.375 billion bond issuance for Appalachian Power, signaling robust access to credit for large-cap infrastructure. However, a contrasting theme of financial strain is evident in filings from Golden Minerals, GridAI, and NanoViricides, which are resorting to dilutive equity offerings or debt settlements to manage liquidity. Leadership changes are widespread, with notable CEO departures at Choice Hotels and Clean Harbors, and CFO transitions at Philip Morris, Skillz, and Stryker, suggesting a period of corporate recalibration. While most governance filings (annual meeting results) were routine, the aggregate data points to a bifurcated market where large, well-capitalized firms are optimizing their balance sheets, while smaller entities face existential funding challenges. The overall sentiment is mixed, with a tilt toward cautious optimism in the energy and infrastructure sectors, contrasted by heightened risk in small-cap biotech and mining.

50 high priority 50 total filings
· daily

Dow Jones 30 Stocks SEC Filings — May 20, 2026

The 50 filings from the USA Dow Jones 30 intelligence stream, dominated by constituent and related-ecosystem companies, reveal a broadly positive but cautious economic landscape for May 2026. A clear theme is strong semiconductor demand, with Analog Devices reporting a 37% YoY revenue surge and record bookings, signaling robust industrial and communications end-markets. Concurrently, other cyclical sectors show divergent strength, including Dorian LPG's revenue more than doubling (+102% YoY) on a 75% jump in Baltic LPG rates. However, the data also exposes a two-tier market: while industrial and energy names thrive, several pre-revenue biotech and micro-cap firms are burning cash at alarming rates, with widened net losses and negative equity positions. Capital allocation trends are mixed; some firms are aggressively cutting debt (V.F. Corp reduced leverage from 4.1x to 3.1x) while others opt for stock-based interest payments (Wheeler REIT). Insider trading activity is limited in this batch, but management-led buyouts (Select Medical Holdings) and significant M&A (Red Cat's acquisition) signal conviction in specific strategic paths. Forward-looking guidance from ADI and V.F. Corp indicates continued but measured growth, while cybersecurity risks have emerged as a material operational threat, as seen in the West Pharmaceutical Services attack. The overall picture is one of uneven growth, where strong operational performance at the index level coexists with significant distress in smaller, cash-constrained entities.

27 high priority 23 medium 50 total filings
· daily

US SEC Filings Daily Market Digest — May 20, 2026

Today's filings reveal a bifurcated market with strong growth in select industrials and tech (Analog Devices +37% YoY, Dorian LPG +102% YoY, CAVA +32% YoY) contrasting with sharp declines in energy and small-cap names (PrimeEnergy -52.5% net income, Cavitation Technologies -97.5% revenue). The most critical development is the proposed $3.4B transformational merger of Sachem Capital with IRG, which could create a top-10 industrial REIT but carries significant execution risk. Insider activity is notably absent across filings, but capital allocation patterns show a clear preference for debt reduction and buybacks over dividends. The SPAC market shows renewed activity with FutureCorp's $200M IPO filing, while the crypto space sees institutional validation with Morgan Stanley's Solana and Ethereum trust filings. Portfolio-level trends indicate margin compression in consumer-facing names (CAVA, Hasbro) despite revenue growth, while semiconductor and energy shipping sectors demonstrate exceptional operating leverage.

25 high priority 25 medium 50 total filings
· daily

S&P 500 Consumer Discretionary Sector SEC Filings — May 20, 2026

This batch of 50 S&P 500 Consumer Discretionary filings reveals a deeply bifurcated landscape. On the positive side, **e.l.f. Beauty** reported exceptional 35% YoY revenue growth and **VF Corp** showed a strong Americas turnaround (+10% C$ ex-Dickies), while **Flex Ltd** posted 8.1% revenue growth driven by cloud infrastructure. However, these bright spots are overshadowed by widespread margin compression and deteriorating profitability. Key financial indicators show 5 companies with net losses widening by over 100% YoY and 3 companies with revenue declines. Insider activity is notably absent, with no major buying or selling signals from management across the filings. Capital allocation trends are defensive, with **Starbucks** completing $1.32B in debt buybacks and **United Fire Group** extending share repurchase authority, while dividend policies remain stable. The most critical development is **Six Flags** entering a cooperation agreement with activist investor H Partners, signaling potential operational changes in the entertainment sector. Sector-wide risks include tariff-driven cost pressures in imported goods (retail/apparel), potential recession dampening discretionary spending, and rising input costs in automotive and consumer electronics. **FG Merger II Corp**'s planned merger with modular housing company Boxabl highlights a growing SPAC trend in housing innovation.

22 high priority 28 medium 50 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — May 20, 2026

The 50 filings for the S&P 500 Healthcare stream reveal a sector bifurcated between large-cap innovators executing capital market maneuvers and small/mid-cap firms facing acute financial distress. Eli Lilly and Gilead Sciences raised a combined ~$12 billion in debt, signaling a period of aggressive M&A and pipeline investment, while Roivant Sciences posted a massive $2.25 billion settlement gain but saw R&D expenses surge 37%. Conversely, several micro-cap biotechs (e.g., Klotho Neurosciences, Lifeward) reported widening net losses of 555% and 125% YoY, respectively, highlighting a cash-burn crisis. A key period-over-period trend is the divergence in revenue performance: Pacira BioSciences reported record revenue with 5-21% product growth, while Scilex Holding grew revenue 72% but saw its net loss balloon 75% due to non-cash charges. Insider activity was notably absent from the filings, but proxy fights (Pacira vs. DOMA) and shareholder dissent (Amgen's independent chairman proposal rejected 4.6:1) signal governance tensions. Capital allocation is a mixed bag, with Zoetis maintaining a stable dividend and Stryker executing a planned CFO transition, while distressed firms like Renewal Fuels and Citrine Global burn cash with no path to profitability. The overarching theme is a 'flight to quality' where only companies with strong balance sheets and clear catalysts (e.g., Roivant's brepocitinib NDA) are positioned to thrive.

21 high priority 29 medium 50 total filings
· daily

US Executive Compensation Proxy SEC Filings — May 20, 2026

This intelligence stream analyzes 8 DEF 14A proxy filings for the 2026 annual meeting season, revealing a concentrated focus on capital structure management and governance transitions. A dominant theme is the prevalence of reverse stock split proposals (Longeveron, Oragenics) and share issuance authorizations (Blink Charging, MSC Income Fund), signaling that several small-cap and micro-cap companies are actively managing stock price compliance or raising capital. Insider trading activity is notably absent across all filings, providing no direct management conviction signals. Period-over-period comparisons are largely unavailable as these proxy statements focus on governance proposals rather than financial performance. However, the filings reveal a clear pattern of companies seeking to increase equity incentives (Blink Charging, Workhorse) and authorize below-NAV share sales (MSC Income Fund), indicating a focus on retaining talent and accessing capital markets. The most critical development is the high concentration of annual meetings in late June 2026, creating a catalyst calendar for governance votes that could impact stock liquidity and dilution. Overall, the filings suggest a cautious capital allocation environment with an emphasis on survival and flexibility rather than aggressive growth.

8 high priority 8 total filings
· daily

US IPO Pipeline SEC S-1 Filings — May 20, 2026

The IPO pipeline on May 20, 2026, is dominated by high-profile, high-growth names, including SpaceX and Medline, alongside a traditional SPAC (FutureCorp) and a nuclear energy play (Deep Fission). A key theme is the prevalence of secondary offerings and insider monetization, most notably Medline's filing by pre-IPO owners (Blackstone, Carlyle, H&F) and SpaceX's dual-class structure ensuring Elon Musk's control. The Skyworks/Qorvo S-4 filing, while not an IPO, signals significant M&A activity in the semiconductor sector, with a $1.55B debt exchange offer. Period-over-period data reveals strong revenue growth trajectories, with Medline boasting an 18% CAGR since inception and Picard Medical showing a 15% YoY revenue increase. However, dilution risks are acute: FutureCorp's sponsor acquired founder shares at $0.004 vs. the $10.00 IPO price, and Medline's secondary offering could pressure the stock. The overall sentiment is mixed, balancing high-growth opportunities against significant dilution and governance risks.

6 high priority 6 total filings
· daily

Global High-Priority Regulatory Events — May 20, 2026

This intelligence stream reveals a bifurcated market landscape on May 20, 2026, characterized by severe distress in small-cap and micro-cap companies, counterbalanced by robust growth and strategic positioning in larger, more established firms. The most critical developments include a delisting and Chapter 11 bankruptcy filing by Society Pass Inc., alongside a wave of negative earnings surprises and widening losses across a cohort of micro-cap entities (Powerdyne, Renewal Fuels, AppYea, Starfighters Space). Conversely, Analog Devices reported a standout 37% YoY revenue surge, while Apollo Hospitals delivered 18% top-line growth and a 31% EBITDA increase, signaling strong sector-specific demand. A significant trend is the aggressive capital market activity, with multiple SPAC IPOs (FutureCorp Space, Deep Fission) and crypto-asset trust filings (Morgan Stanley for Solana and Ethereum) indicating sustained institutional appetite for thematic and speculative assets. Period-over-period data shows a clear pattern of revenue growth failing to translate to profitability for many growth-stage companies, with operating expenses and non-cash charges eroding bottom lines. Insider activity was notably absent, but capital allocation decisions—such as debt refinancing by Avista Corp. and a $3.75B credit facility for Williams Companies—point to a focus on liquidity management. The overall sentiment is mixed, with high materiality events concentrated in bankruptcy, regulatory actions, and transformative M&A, demanding immediate attention from event-driven investors.

50 high priority 50 total filings